Significantly Improved HIV Inhibitor Efficacy Prediction Employing Proteochemometric Models Generated From Antivirogram Data

PLoS Computational Biology

Volumn 9, Issue 2, 2013, Pages

  van Westen, Gerard J P ^a,d   Hendriks, Alwin ^a   Wegner, Jörg K ^b   IJzerman, Adriaan P ^a   van Vlijmen, Herman W T ^a,b   Bender, Andreas ^a,c  

^a LEIDEN UNIVERSITY   (Netherlands)

^b TIBOTEC BVBA   (Belgium)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOACTIVITY; PATIENT TREATMENT;

ADDED VALUES; CHEMICAL SIMILARITY; COMBINATION TREATMENTS; COMPUTATIONAL MODELLING; CURRENT MODELING; DRUG COMBINATIONS; GENOTYPING; OPTIMAL TREATMENT; PHENOTYPIC DATA; SEQUENCE DATA;

FORECASTING;

ANTIRETROVIRUS AGENT; ATAZANAVIR; DARUNAVIR; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TIPRANAVIR;

ANTIVIRAL RESISTANCE; ARTICLE; CHEMICAL ANALYSIS; CHEMICAL DATABASE; CHEMOMETRIC ANALYSIS; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG MECHANISM; GENETIC DATABASE; GENOTYPE; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; MONOTHERAPY; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PREDICTION; PROCESS MODEL; PROSPECTIVE STUDY; PROTEIN ANALYSIS; PROTEIN TARGETING; PROTEOCHEMOMETRIC MODEL; RELIABILITY; STRUCTURE ACTIVITY RELATION; VALIDATION PROCESS; VIRUS INHIBITION; VIRUS MUTATION;

EID: 84874779833     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1002899     Document Type: Article

References (65)

1. Barre-Sinoussi F, Chermann J, Rey F, Nugeyre M, Chamaret S, et al. (1983) Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 220: 868-871.
2. Popovic M, Sarngadharan M, Read E, Gallo R, (1984) Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science 224: 497-500.
3. UNAIDS (2011) Progress Report: Global HIV/AIDS Response. Geneva, Switserland: UNAIDS.
4. Kaufmann D, Pantaleo G, Sudre P, Telenti A, (1998) CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Swiss HIV Cohort Study. Lancet 351: 723-724.
5. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, et al. (1998) Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus Infection. N Engl J Med 338: 853-860.
6. Johnson VA, Calvez V, Günthard HF, Paredes R, Pillay D, et al. (2011) 2011 update of the drug resistance mutations in HIV-1. Top Antivir Med 19: 156-164.
7. Preston B, Poiesz B, Loeb L, (1988) Fidelity of HIV-1 reverse transcriptase. Science 242: 1168-1171.
8. Roberts J, Bebenek K, Kunkel T, (1988) The accuracy of reverse transcriptase from HIV-1. Science 242: 1171-1173.
9. Hertogs K, Bloor S, Kemp SD, Eynde CVd, Alcorn TM, et al. (2000) Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples. AIDS 14: 1203-1210.
10. Carpenter CCJ, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, et al. (2000) Antiretroviral Therapy in Adults. JAMA 283: 381-390.
11. Perrin L, Telenti A, (1998) HIV Treatment Failure: Testing for HIV Resistance in Clinical Practice. Science 280: 1871-1873.
12. Hertogs K, de Bethune M-P, Miller V, Ivens T, Schel P, et al. (1998) A Rapid Method for Simultaneous Detection of Phenotypic Resistance to Inhibitors of Protease and Reverse Transcriptase in Recombinant Human Immunodeficiency Virus Type 1 Isolates from Patients Treated with Antiretroviral Drugs. Antimicrob Agents Chemother 42: 269-276.
13. Petropoulos CJ, Parkin NT, Limoli KL, Lie YS, Wrin T, et al. (2000) A Novel Phenotypic Drug Susceptibility Assay for Human Immunodeficiency Virus Type 1. Antimicrob Agents Chemother 44: 920-928.
14. Walter H, Schmidt B, Korn K, Vandamme A-M, Harrer T, et al. (1999) Rapid, phenotypic HIV-1 drug sensitivity assay for protease and reverse transcriptase inhibitors. J Clin Virol 13: 71-80.
15. Van Laethem K, De Luca A, Antinori A, Cingolani A, Perna CF, et al. (2002) A genotypic drug resistance interpretation algorithm that significantly predicts therapy response in HIV-1-infected patients. Antivir Ther 7: 123-129.
16. De Luca A, Cingolani A, Di Giambenedetto S, Trotta MP, Baldini F, et al. (2003) Variable Prediction of Antiretroviral Treatment Outcome by Different Systems for Interpreting Genotypic Human Immunodeficiency Virus Type 1 Drug Resistance. J Infect Dis 187: 1934-1943.
17. Meynard J-L, Vray M, Morand-Joubert L, Race E, Descamps D, et al. (2002) Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. AIDS 16: 727-736.
18. Shafer Robert W, (2006) Rationale and Uses of a Public HIV Drug-Resistance Database. J Infect Dis 194: S51-S58.
19. Altmann A, Däumer M, Beerenwinkel N, Peres Y, Schülter E, et al. (2009) Predicting the Response to Combination Antiretroviral Therapy: Retrospective Validation of geno2pheno-THEO on a Large Clinical Database. J Infect Dis 199: 999-1006.
20. Beerenwinkel N, Daumer M, Oette M, Korn K, Hoffmann D, et al. (2003) Geno2pheno: Estimating phenotypic drug resistance from HIV-1 genotypes. Nucleic Acids Res 31: 3850-3855.
21. Perez-Elias MJ, Garcia-Arota I, Munoz V, Santos I, Sanz J, et al. (2003) Phenotype or virtual phenotype for choosing antiretroviral therapy after failure: a prospective, randomized study. Antivir Ther 8: 577-584.
22. Ratner L, Haseltine W, Patarca R, Livak KJ, Starcich B, et al. (1985) Complete nucleotide sequence of the AIDS virus, HTLV-III. Nature 313: 277-284.
23. Korber BT, Foley BT, Kuiken CL, Pillai SK, Sodroski JG (1998) Numbering Positions in HIV Relative to HXB2CG. Los Alamos: Los Alamos National Laboratory.
24. Adachi A, Gendelman HE, Koenig S, Folks T, Willey R, et al. (1986) Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol 59: 284-291.
25. Vermeiren H, Van Craenenbroeck E, Alen P, Bacheler L, Picchio G, et al. (2007) Prediction of HIV-1 drug susceptibility phenotype from the viral genotype using linear regression modeling. J Virol Methods 145: 47-55.
26. DiRienzo A, DeGruttola V, Larder B, Hertogs K, (2003) Non-parametric methods to predict HIV drug susceptibility phenotype from genotype. Stat Med 22: 2785-2798.
27. Lim HC, Curlin ME, Mittler JE, (2011) HIV Therapy Simulator: a graphical user interface for comparing the effectiveness of novel therapy regimens. Bioinformatics 27: 3065-3066.
28. Beerenwinkel N, Lengauer T, Daumer M, Kaiser R, Walter H, et al. (2003) Methods for optimizing antiviral combination therapies. Bioinformatics 19: i16-i25.
29. Bender A, Glen RC, (2004) Molecular similarity: a key technique in molecular informatics. Org Biomol Chem 2: 3204-3218.
30. Lapins M, Eklund M, Spjuth O, Prusis P, Wikberg J, (2008) Proteochemometric modeling of HIV protease susceptibility. BMC Bioinformatics 9: 181-192.
31. Kontijevskis A, Petrovska R, Yahorava S, Komorowski J, Wikberg JES, (2009) Proteochemometrics mapping of the interaction space for retroviral proteases and their substrates. Bioorg Med Chem 17: 5229-5237.
32. Van Westen GJP, Wegner JK, IJzerman AP, Van Vlijmen HWT, Bender A, (2011) Proteochemometric Modeling as a Tool for Designing Selective Compounds and Extrapolating to Novel Targets. MedChemComm 2: 16-30.
33. Van Westen GJP, Wegner JK, Geluykens P, Kwanten L, Vereycken I, et al. (2011) Which Compound to Select in Lead Optimization? Prospectively Validated Proteochemometric Models Guide Preclinical Development. PLoS One 6: e27518.
34. Lapins M, Wikberg JES, (2009) Proteochemometric Modeling of Drug Resistance over the Mutational Space for Multiple HIV Protease Variants and Multiple Protease Inhibitors. J Chem Inf Model 49: 1202-1210.
35. Junaid M, Lapins M, Eklund M, Spjuth O, Wikberg JES, (2010) Proteochemometric Modeling of the Susceptibility of Mutated Variants of the HIV-1 Virus to Reverse Transcriptase Inhibitors. PLoS One 5: e14353.
36. Tropsha A (2010) Predictive Quantitative Structure-Activity Relationships Modeling. In: Faulon J, Bender A, editors. Handbook of Chemoinformatics Algorithms.
37. Tropsha A, Golbraikh A, (2007) Predictive QSAR Modeling Workflow, Model Applicability Domains, and Virtual Screening. Curr Pharm Des 13: 3494-3504.
38. Patterson DE, Cramer RD, Ferguson AM, Clark RD, Weinberger LE, (1996) Neighborhood Behavior: A Useful Concept for Validation of "Molecular Diversity" Descriptors. J Med Chem 39: 3049-3059.
39. Van der Borght K, Van Craenenbroeck E, Lecocq P, Van Houtte M, Van Kerckhove B, et al. (2011) Cross-validated stepwise regression for identification of novel non-nucleoside reverse transcriptase inhibitor resistance associated mutations. BMC Bioinformatics 12: 386.
40. Johnson V, Brun Vezinet F, Clotet B, Kuritzkes D, Pillay D, et al. (2006) Update of the drug resistance mutations in HIV-1: Fall 2006. Top HIV Med 14: 125-130.
41. Vingerhoets J, Peeters M, Azjin H, Tambuyzer L, Hoogstoel A, et al. (2008) An update of the list of NNRTI mutations associated with decreased virological response to etravirine: multivariate analysis on the pooled DUET-1 and DUET-2 clinical trial data [abstract 24]. Antivir Ther 13: Suppl 3: A26.
42. Shafer RW, Schapiro JM, (2008) HIV-1 drug resistance mutations: an updated framework for the second decade of HAART. AIDS Rev 10: 67-84.
43. Perno CF, Svicher V, Ceccherini-Silberstein F, (2006) Novel drug resistance mutations in HIV: recognition and clinical relevance. AIDS Rev 8: 179-190.
44. Rhee S-Y, Taylor J, Wadhera G, Ben-Hur A, Brutlag DL, et al. (2006) Genotypic predictors of human immunodeficiency virus type 1 drug resistance. Proc Natl Acad Sci U S A 103: 17355-17360.
45. Emini EA, Graham DJ, Gotlib L, Condra JH, Byrnes VW, (1993) HIV and multidrug resistance. Nature 364: 679-679.
46. Tisdale M, Kemp SD, Parry NR, Larder BA, (1993) Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci U S A 90: 5653-5656.
47. Byrnes VW, Emini EA, Schleif WA, Condra JH, Schneider CL, et al. (1994) Susceptibilities of human immunodeficiency virus type 1 enzyme and viral variants expressing multiple resistance-engendering amino acid substitutions to reserve transcriptase inhibitors. Antimicrob Agents Chemother 38: 1404-1407.
48. Imamichi T, Sinha T, Imamichi H, Zhang Y-M, Metcalf JA, et al. (2000) High-Level Resistance to 3′-Azido-3′-Deoxythimidine due to a Deletion in the Reverse Transcriptase Gene of Human Immunodeficiency Virus Type 1. J Virol 74: 1023-1028.
49. Paolucci S, Baldanti F, Maga G, Cancio R, Zazzi M, et al. (2004) Gln145Met/Leu Changes in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Confer Resistance to Nucleoside and Nonnucleoside Analogs and Impair Virus Replication. Antimicrob Agents Chemother 48: 4611-4617.
50. Zolopa AR, Lazzeroni LC, Rinehart A, Vezinet FB, Clavel F, et al. (2005) Accuracy, Precision, and Consistency of Expert HIV Type 1 Genotype Interpretation: An International Comparison (The GUESS Study). Clin Infect Dis 41: 92-99.
51. Van Houtte M, Picchio G, Van Der Borght K, Pattery T, Lecocq P, et al. (2009) A comparison of HIV-1 drug susceptibility as provided by conventional phenotyping and by a phenotype prediction tool based on viral genotype. J Med Virol 81: 1702-1709.
52. Sandberg M, Eriksson L, Jonsson J, Sjostrom M, Wold S, (1998) New Chemical Descriptors Relevant for the Design of Biologically Active Peptides. A Multivariate Characterization of 87 Amino Acids. J Med Chem 41: 2481-2491.
53. Hellberg S, Sjoestroem M, Skagerberg B, Wold S, (1987) Peptide quantitative structure-activity relationships, a multivariate approach. J Med Chem 30: 1126-1135.
54. Glen RC, Bender A, Arnby CH, Carlsson L, Boyer S, et al. (2006) Circular fingerprints: Flexible molecular descriptors with applications from physical chemistry to ADME. IDrugs 9: 199-204.
55. Rogers D, Hahn M, (2010) Extended-Connectivity Fingerprints. J Chem Inf Model 50: 742-754.
56. Accelrys Software Inc Pipeline Pilot Student Edition. Version 6.1.5 ed: Scitegic.
57. Bender A, Jenkins JL, Scheiber J, Sukuru SCK, Glick M, et al. (2009) How Similar Are Similarity Searching Methods? A Principal Component Analysis of Molecular Descriptor Space. J Chem Inf Model 49: 108-119.
58. Willett P, Barnard JM, Downs GM, (1998) Chemical Similarity Searching. J Chem Inf Comput Sci 38: 983-996.
59. R Development Core Team (2006) R: A Language and Environment for Statistical Computing.
60. Dimitriadou E, Hornik K, Leisch F, Meyer D, Weingessel A (2006) Misc Functions of the Department of Statistics (e1071). 1.5-15 ed. Wien: TU Wien.
61. Vapnik V (1995) The Nature of Statistical Learning. New York: Springer.
62. Golbraikh A, Tropsha A, (2002) Beware of q2!. J Mol Graph Model 20: 269-276.
63. Wang K, Samudrala R, Mittler J, (2004) Weak Agreement between Antivirogram and PhenoSense Assays in Predicting Reduced Susceptibility to Antiretroviral Drugs. J Clin Microbiol 42: 2353-2354.
64. Wang K, Samudrala R, Mittler J, (2004) Antivirogram or phenosense: a comparison of their reproducibility and an analysis of their correlation. Antivir Ther 9: 703-712.
65. Zhang J, Rhee S-Y, Taylor J, Shafer RW, (2005) Comparison of the Precision and Sensitivity of the Antivirogram and PhenoSense HIV Drug Susceptibility Assays. JAIDS J Acquir Immune Defic Syndr 38: 439-444.